BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 35340171)

  • 21. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series.
    Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H
    Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer.
    Veen T; Kanani A; Lea D; Søreide K
    Cancer Immunol Immunother; 2023 Oct; 72(10):3135-3147. PubMed ID: 37528319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of preoperative mFOLFOX6 regimen chemotherapy for locally resectable advanced rectal cancer.
    Liu L; Jiang Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Jan; 46(1):32-38. PubMed ID: 33678634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
    Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
    Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Neoadjuvant immunotherapy for colorectal cancer].
    Pei JP; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):58-67. PubMed ID: 36650001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.
    Yu JH; Xiao BY; Li DD; Jiang W; Ding Y; Wu XJ; Zhang RX; Lin JZ; Wang W; Han K; Kong LH; Zhang XK; Chen BY; Mei WJ; Pan ZZ; Tang JH; Zhang XS; Ding PR
    Lancet Oncol; 2024 Jun; ():. PubMed ID: 38852601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer.
    Xiao BY; Zhang X; Cao TY; Li DD; Jiang W; Kong LH; Tang JH; Han K; Zhang CZ; Mei WJ; Xiao J; Pan ZZ; Li YF; Zhang XS; Ding PR
    J Natl Compr Canc Netw; 2023 Jan; 21(1):60-66.e5. PubMed ID: 36630898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI-H/dMMR rectal cancer: A prospective, multicenter, phase Ib study.
    Li X; Fang C; Wang X; Yu Y; Wang Z; Qiu M
    Cancer Med; 2022 Dec; 11(23):4405-4410. PubMed ID: 35352512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer in real world.
    Fang M; Hang Q; Jiang H; Cai L; Hu J; Ying H; Gu Q; Yu X; Liu J; Lai X
    Front Oncol; 2022; 12():1055610. PubMed ID: 36713546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
    Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer.
    Kanani A; Veen T; Søreide K
    Br J Surg; 2021 Dec; 108(12):1417-1425. PubMed ID: 34694371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 33. [Application of endoscopic tattooing with carbon nanoparticlet in the treatment for advanced colorectal cancer].
    Wang R; Zhan HL; Li DZ; Li HT; Yu L; Wang W
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):56-64. PubMed ID: 31958932
    [No Abstract]   [Full Text] [Related]  

  • 34. [Postoperative short-term complications of laparoscope-assisted transanal total mesorectal excision for rectal cancer after neoadjuvant therapy and their management: a single center report].
    Liu X; He G; Li Y; Dong Q; Zhang X; Sun T; Wang L; Yao Y; Wu A
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Mar; 22(3):255-261. PubMed ID: 30919378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study.
    Yang R; Wu T; Yu J; Cai X; Li G; Li X; Huang W; Zhang Y; Wang Y; Yang X; Ren Y; Hu R; Feng Q; Ding P; Zhang X; Li Y
    Front Immunol; 2023; 14():1182299. PubMed ID: 37441082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of neoadjuvant immunotherapy in advanced colorectal cancer: a meta-analysis of cross-sectional studies.
    Li Y; Xue C; Gao Z; Li K; Xu H; Zhu Z
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4839-4846. PubMed ID: 36260157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical features and risk factors of surgical complications after intersphincteric resection for low rectal cancer following neoadjuvant chemoradiotherapy].
    Qin QY; Ma TH; Cai J; Huang XY; Wu YL; Wang HM; Wang H; Wang L
    Zhonghua Wai Ke Za Zhi; 2018 Dec; 56(12):892-899. PubMed ID: 30497115
    [No Abstract]   [Full Text] [Related]  

  • 38. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
    André T; Tougeron D; Piessen G; de la Fouchardière C; Louvet C; Adenis A; Jary M; Tournigand C; Aparicio T; Desrame J; Lièvre A; Garcia-Larnicol ML; Pudlarz T; Cohen R; Memmi S; Vernerey D; Henriques J; Lefevre JH; Svrcek M
    J Clin Oncol; 2023 Jan; 41(2):255-265. PubMed ID: 35969830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
    Chalabi M; Fanchi LF; Dijkstra KK; Van den Berg JG; Aalbers AG; Sikorska K; Lopez-Yurda M; Grootscholten C; Beets GL; Snaebjornsson P; Maas M; Mertz M; Veninga V; Bounova G; Broeks A; Beets-Tan RG; de Wijkerslooth TR; van Lent AU; Marsman HA; Nuijten E; Kok NF; Kuiper M; Verbeek WH; Kok M; Van Leerdam ME; Schumacher TN; Voest EE; Haanen JB
    Nat Med; 2020 Apr; 26(4):566-576. PubMed ID: 32251400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.